This finding contrasts with a previous report documenting FOXA1 upregulation in the cisplatin-resistant NPC cell line CNE2/DDP, where FOXA1 knockdown conversely improved cisplatin sensitivity [38]. The gene discussed is FOXA1; the disease is nasopharyngeal carcinoma.